Articles tagged with Cancer Immunotherapy
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Recent studies have highlighted the importance of tumor microenvironment in developing and controlling triple negative breast cancer progression. Researchers suggest that technological advancements like genomics and epigenomics hold promise for overcoming TNBC's current limitations.
The study reveals that intratumoral natural killer cells' loss of membrane protrusions impairs their ability to recognize and kill tumor cells. Researchers developed a single-immunocyte mass spectrometry technology to detect the decrease in sphingomyelin, which can restore protrusion formation and improve NK cells' killing capacity.
Researchers have identified a biomarker signature that can predict which patients with kidney cancer will respond well to immunotherapy. The signature is based on the number of immune cells in and around tumors, the amount of dead cancer tissue, and mutations to a tumor suppressor gene called PBRM1.
Researchers found that probiotic bacteria Lactobacillus reuteri stimulates cancer-killing T cells by secreting indole-3-aldehyde, which activates a receptor in CD8 cells. A diet rich in tryptophan enhances the effect of immunotherapy on shrinking tumors and prolonging survival.
Cancer-associated fibroblasts (CAFs) are a type of cell that plays a crucial role in the tumor microenvironment. The authors suggest that understanding CAFs is essential for developing effective cancer therapies. Research targeting CAFs has shown promise, but challenges remain due to their complex nature.
An international panel of experts has developed standardized definitions for immunotherapy side effects, providing a shared vocabulary for clinicians to standardize clinical practice guidelines. This will help support clinicians in offering the best treatment to patients and enable research into biomarkers predicting adverse effects.
Researchers developed 'BioArm,' a portable 3D bioprinter for cancer research, which can print complex tumoroids in under 90 seconds. The device enables testing of immunotherapy treatments and mimics the tumor microenvironment.
A study published in the journal Cancer found that long-term pancreatic cancer survivors have a robust immune response and enriched gut microbiome species, including Faecalibacterium prausnitzii. The research suggests that these bacterial species may promote immune response to pancreas cancer.
A phase 2 study found a 92% disease control rate with the combination of belzutifan and cabozantinib in pre-treated advanced kidney cancer patients. The treatment has a manageable safety profile, providing a potential alternative for patients experiencing disease progression on immunotherapy.
Researchers found that neutrophils activated by T cell-based immunotherapy can kill tumor cells that evade targeted therapies. This unexpected antitumor response could lead to new immunotherapies that harness this potent immune mechanism.
Researchers found that neutrophils can be pro- or anti-tumour depending on their surface markers, and those fighting tumours share cytotoxic power with neutrophils in bacterial infections. Blocking these anti-tumour neutrophils eliminates treatment benefits.
Cancer cells have been found to employ a strategy to evade the immune system's killer T cells by interacting with myeloid cells and suppressing type 1 interferon production. This natural pathway is crucial for recruiting killer T cells to combat cancer spread. Researchers hope to develop new therapeutic approaches, such as forcing tumo...
Researchers at University of California San Diego School of Medicine found a significant reduction in disease growth when combining immunotherapy with chemotherapy in patients with advanced endometrial cancer. The study resulted in a 70% risk reduction in the deficient mismatch repair group.
Researchers at Moffitt Cancer Center have discovered a combination strategy that targets the STING signaling pathway, resulting in improved antitumor activity. Inhibiting methylation increases STING expression and activates immune cells, leading to enhanced antitumor immunity.
Researchers discovered that cancer cells' glycocalyx thickness affects immune cell evasion and engineered immune cells work better with thinner barriers. They also developed special enzymes to overcome the barrier, potentially improving immunotherapies.
Researchers discovered over 500 non-canonical protein-derived peptides that could be recognized by T-cells, but found no spontaneous immune response. Three novel T-cell receptors were identified for specific non-canonical HLA-I tumor ligands with promising tumor specificity.
Researchers found that immunotherapy can activate tumor-fighting T cells in nearby lymph nodes, potentially boosting efficacy against solid tumors. The study suggests leaving lymph nodes intact until after immunotherapy could improve treatment outcomes for patients with head and neck cancers.
A Phase II trial led by researchers from the University of Texas MD Anderson Cancer Center demonstrated that adding ipilimumab to a neoadjuvant combination of nivolumab plus platinum-based chemotherapy resulted in a major pathologic response in half of all treated patients with early-stage non-small cell lung cancer. The treatment also...
A comprehensive analysis of invasive ER+ breast cancers found macrophages as dominant immune cells infiltrating tumors. The study identified distinct immune cell 'neighborhoods' associated with good patient outcomes and highlights the need for tailored immunotherapies targeting macrophages.
Researchers at Karolinska Institutet discovered an immune cell in women with pancreatic cancer that blocks the immune response, leading to poor survival. The study identifies a specific protein FPR2 as a potential therapeutic target for immunotherapy in women.
Researchers have developed CAR T cell-based microrobots that can autonomously navigate to tumor sites and exert immune effects. The M-CAR T demonstrated controllable movement and penetrated artificial tumor tissues under magnetic-acoustic sequential actuation.
Researchers discovered that tumors with specific genetic mutations may evade the immune system, and a new class of immunotherapies targets these cells. The study's findings suggest that genetic testing could identify patients more likely to benefit from these therapies.
A new study found that antibiotic treatment and certain types of microorganisms in the gut can impact CAR T-cell therapy outcomes. Patients with higher levels of Bifidobacterium longum had improved overall survival rates, while those with other bacteria were associated with poorer responses.
Researchers have identified two potential molecular targets, CSF1R and CD86, that can be used to develop CAR-T cells effective against acute myeloid leukemia. The study's findings demonstrate the potential of AI-assisted analysis in discovering new treatment options.
Researchers found that a healthy gut microbiome can predict the efficacy of CAR-T cell therapy in patients with B-cell lymphomas. The study identified specific microbiome features associated with improved treatment outcomes, but highlights the need for further investigation into the causal nature of this relationship.
Researchers at Garvan Institute of Medical Research found that introducing bacteria to a tumor's microenvironment triggers an immune response, activating neutrophils to destroy tumors in animal models. This breakthrough therapy targets neutrophils to improve cancer treatment outcomes.
A biological messenger called interleukin-33 (IL-33) plays a crucial role in maintaining cytotoxic T cells' 'marathon runner' state, allowing them to provide sustained immunity against chronic infections. This finding has implications for improving treatment of hepatitis C and cancer immunotherapy.
Lung cancer patients with moderate to severe depression are 2-3 times more likely to have inflammation levels that predict poor survival rates, according to a new study. The results suggest depression may be as important or even more important than other factors in determining lung cancer outcomes.
Researchers discovered a new personalized immunotherapy combination that treats aggressive forms of advanced prostate cancer. By blocking PD-1-expressing macrophages and Wnt/β-catenin pathway activation, the therapy significantly improves response rates in PTEN-deficient cancers.
Patients with stage IIIB-IV melanoma who received neoadjuvant pembrolizumab had a significantly lower risk of cancer recurrence compared to those receiving adjuvant therapy only. The study found improved event-free survival rates in the neoadjuvant group, suggesting that starting immunotherapy before surgery generates better outcomes.
The NCCN Annual Conference will debut a new hybrid format featuring in-person events at a new venue, allowing for hallway conversations and networking opportunities. The conference will also showcase more than 100 abstract poster presentations on various oncology-related categories.
A recent study found that immunotherapy costs accounted for 84% of the net increase in Medicare spending on outpatient cancer care at the end of life. Payments for radiation oncology decreased by 2%, while palliative care spending rose, reflecting a shift towards hypofractionated radiation treatments.
Researchers found that combining a chemical blocker of immune cell exit with immunotherapy stopped melanoma tumor enlargement in over half of mice tested. The study showed that T cells circulate out of tumors, reshaping scientific views of tumor immunology.
The ESMO Targeted Anticancer Therapies Congress 2023 features presentations on drug discovery and development for various targets, precision medicine, and early clinical trial methodology. Keynote lectures highlight novel insights in mutational signatures and epigenetic therapies.
A recent study suggests that routine evaluation of HER2 expression in ductal carcinoma in situ (DCIS) is crucial to avoid under or overtreatment. The research found a significant association between HER2 overexpression and a higher risk of recurrence, as well as improved radiotherapy outcomes.
Researchers discovered that combining ferroptosis induction with immune checkpoint inhibition reduces liver tumour growth and metastases, offering a promising new approach for treating liver cancer
Researchers have discovered that cancer patients who don't respond to immunotherapy often lack CD5+ dendritic cells, which are essential for effective T cell activity. Boosting these cells may help more patients benefit from immunotherapy.
Researchers developed a computational tool called BipotentR that identifies targets to block immune activation while stimulating metabolism. The tool predicted patients' outcomes after immunotherapy and identified ESRRA as the top regulator.
Researchers at Uppsala University developed a prognostic method using a combination of immune cells to provide clearer disease prognoses and predict which patients will respond best to immunotherapy. The method was shown to be associated with patient fate in several types of cancer.
Researchers developed a novel pH-activated nanocytokine system using IL-12, which enhances immunity and eradicates tumors in murine models. The nanocytokine controls inflammation through spatiotemporal regulation, blocking counteractive immune responses and reducing toxicity.
The study validated the clinical utility of Strata Oncology's proprietary pan-solid tumor predictive biomarker, Immunotherapy Response Score (IRS), which predicts response to checkpoint inhibitor therapy. IRS captures tumor biology and microenvironment by combining tumor mutation burden with quantitative expression of PD-L1, PD-1, ADAM...
Researchers at Karolinska Institutet have developed a new type of CAR T-cell therapy that effectively attacks and destroys ovarian cancer cells, significantly prolonging the lives of mice with the disease. The treatment has shown promising results in reducing tumor size and curing several mice.
Researchers at Massachusetts General Hospital found that losartan can reduce the expression of inflammatory enzymes responsible for immunotherapy-related edema. The study suggests that losartan may allow patients to continue receiving immune checkpoint inhibitors without developing adverse effects in the brain.
A research team from HKUMed identified chronic Type I Interferon signalling as a driver of CD8+ T cell exhaustion and therapy resistance. The study highlights the harmful effect of IFN-I on tumour-killing CD8+ T cells, providing new insights into immunotherapy improvement.
The world's first international clinical guidelines have been created to prevent and treat heart complications in children undergoing cancer treatment. The guidelines cover cardiovascular disease assessment, screening, and follow-up for pediatric patients receiving various cancer treatments.
Researchers identified a subset of mutations within tumor mutation burden that remain persistent and visible to the immune system, increasing likelihood of response to immunotherapy. This finding enables clinicians to more accurately select patients for clinical trials or predict clinical outcomes with immune checkpoint blockade.
Moffitt researchers found that administering oral L-fucose increases TILs, reduces tumor growth, and enhances immunotherapy efficacy in animal models. Higher L-fucose levels in melanomas are associated with less aggressive disease and better responses to therapy.
A combination of two novel immunotherapy drugs has shown promising clinical activity in treating patients with refractory metastatic colorectal cancer. The study found that 23% of patients had a tumor reduction, and the disease control rate was 76%. The treatment was well-tolerated, but adverse events were common.
Researchers found that regorafenib, a dual PDGFR α/β inhibitor, modifies the cancer microenvironment and enhances the efficacy of anti-PD-1 immunotherapy in advanced gastric cancers. This combination therapy boosts tumor infiltrating immune cells and reduces tumor fibroblasts.
Researchers found that certain gene signaling pathways, such as interferon γ and beta-catenin, can lead to tumor hyperprogression after immunotherapy. Targeting these pathways may prevent hyperprogression in preclinical models.
Researchers discovered that 15-deoxy-prostamide-J2 induces ER stress-mediated apoptosis selectively in tumor cells, reducing melanoma growth. The molecule activates PERK, IP3R, and the mitochondrial permeability transition pore, leading to cell death.
Researchers at Mass General Hospital identified a gene target, TANK-binding kinase 1 (TBK1), that enhances the effectiveness of cancer immunotherapy. Silencing TBK1 sensitizes tumor cells to immune attack, overcoming resistance to treatment.
Researchers discovered that pre-surgery immunotherapy significantly improved patient outcomes for locally advanced colorectal cancer. The treatment showed substantial longer survival benefits, including low recurrence rates, in patients with mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) CRC.
A new study found that COVID-19 primarily affected patients with a moderate to critical course, often with comorbidities, whereas many had mild courses despite metastatic melanoma and systemic therapy, recommending continued treatment whenever possible.
Scientists have found a way to break down the resistance of mice with neuroendocrine pancreatic cancer to checkpoint blockade immunotherapy. A new drug combination, PD1-IL2v and anti-PD-L1, enhances anti-tumor immunity by stimulating specific T cells and reprogramming macrophages, leading to increased survival rates in tumor-bearing mice.
Researchers identified key metabolic pathways in tumor-associated macrophages that contribute to cancer development and progression. Targeting these pathways may provide a new perspective for immunotherapy-based cancer treatments.
Research from Michigan Medicine reveals that high levels of ammonia in colon tumors can lead to reduced T cell growth and immunotherapy resistance. A study published in Cell Metabolism found that using an FDA-approved drug to lower ammonia levels made tumors more sensitive to treatment.
Researchers found that plasma GH levels are a potential biomarker for predicting treatment outcomes in patients with advanced HCC treated with Atezo/Bev. The study showed significantly superior overall survival and non-significant trend in favor of GH-low patients compared to GH-high patients.
Researchers at the University of Pittsburgh discovered that exhausted cancer-fighting T cells can become immunosuppressive when working in low-oxygen tumor environments. Targeting these conditions can reinvigorate these cells, improving response to immune-based cancer therapies.
A study published in Cancer Research found that the stress response in T cells can hinder cancer immunotherapy. The researchers discovered that targeting key proteins involved in this stress response could help develop more potent cancer immunotherapies.